

**Suppl. Table 1**

STUDY / SOURCE	Imatinib dose, mg	N° of pts	High risk pts (Sokal , Euro)	after 12 months	
				CCyR	MMR
IRIS <sup>15,16</sup>	400	553	18% (S)	68%	38%
HAMMERSMITH <sup>21</sup>	400	224	30% (S)	57%	18%
TOPS <sup>26</sup>	400	157	27% (S)	66%	40%
FRENCH SPIRIT <sup>28</sup>	400	159	24% (S)	58%	38%
ENESTnd <sup>35</sup>	400	283	28% (S)	65%	22%
NORTH AMERICA/CANADA <sup>33</sup>	400	123	28% (S)	69%	44%
DASISION <sup>38</sup>	400	260	19% (E)	72%	28%
BELA <sup>34</sup>	400	252	18% (S)	68%	27%
GIMEMA <sup>29</sup>	400*	559	22% (S)	77%	58%
SEOUL, St. Mary Hospital <sup>32</sup>	400 <sup>#</sup>	363	22% (S)	73%	27%
GERMAN CML STUDY IV <sup>31</sup>	400	325	12% (E)	49%	34%
HOUSTON <sup>25</sup>	800 <sup>§</sup>	258	8% (S)	77%	NR
TIDEL <sup>23</sup>	800	103	33% (S)	88%	47%
TOPS <sup>26</sup>	800	319	23% (S)	70%	46%
GERMAN CML STUDY IV <sup>31</sup>	800	338	14% (E)	63%	46%

\* 600-800 mg in 23% of patients

§ 6-800 mg in 17% of patients    # 400 mg in 19% of patients

NR = Not Reported

**Summary of cytogenetic and molecular response rate at or by 12 months in patients treated firstline with imatinib 400 mg once daily or twice daily (800 mg).**

**Suppl. Table 2**

STUDY / SOURCE	Imatinib dose, mg	N° of pts	High risk pts (Sokal , Euro)	After 12 months	
				CCyR	MMR
IRIS <sup>15</sup>	400	71	100% (S)	49%	38%
ELN <sup>21</sup>	400	108	100% (S)	58%	33%
TOPS <sup>26</sup>	400	42	100% (S)	62%	26%
ENESTnd <sup>35</sup>	400	78	100% (S)	48%	17%
DASISION <sup>38</sup>	400	50	100% (E)	64%	16%
ELN <sup>21</sup>	800	108	100% (S)	64%	40%
TOPS <sup>26</sup>	800	73	100% (S)	63%	40%

**Summary of cytogenetic and molecular response at or by 12 months in high risk patients treated firstline with imatinib, 400 mg once or twice daily.**